AIMS/HYPOTHESIS: Progression to type 1 diabetes is associated with intramolecular epitope spreading to disease-specific antibody epitopes located in the middle region of glutamic acid decarboxylase 65 (GAD65). METHODS: The relationship between intramolecular epitope spreading of autoantibodies specific to GAD65 in relation to the risk of developing type 1 diabetes was tested in 22 high-risk individuals and 38 low-risk individuals. We determined the conformational epitopes in this longitudinal study by means of competition experiments using recombinant Fab of four GAD65-specific monoclonal antibodies. RESULTS: Sera from high-risk children in the preclinical stage recognise a specific combination of GAD65 antibody epitopes located in the middle and the C-terminus of GAD65. High risk of progressing to disease is associated with the emergence of antibodies specific for conformational epitopes at the N-terminus and the middle region. Binding to already established antibody epitopes located in the middle and at the N-terminus increases and shows a significant relation (p=0.005) with HLA, which confers risk of developing diabetes. CONCLUSIONS/ INTERPRETATION: In type 1 diabetes, GAD65 antibodies are initially generated against the middle and C-terminal regions of GAD65. In genetically predisposed subjects the autoimmune response may then undergo intramolecular epitope spreading towards epitopes on the N-terminus and further epitopes located in the middle. These findings clearly demonstrate that the GAD65 autoantibody response in the preclinical stage of type 1 diabetes is dynamic and related to the HLA genotypes that confer risk of diabetes. GAD65-specific Fab should prove useful in predicting progression from islet autoimmunity to clinical onset of type 1 diabetes.
AIMS/HYPOTHESIS: Progression to type 1 diabetes is associated with intramolecular epitope spreading to disease-specific antibody epitopes located in the middle region of glutamic acid decarboxylase 65 (GAD65). METHODS: The relationship between intramolecular epitope spreading of autoantibodies specific to GAD65 in relation to the risk of developing type 1 diabetes was tested in 22 high-risk individuals and 38 low-risk individuals. We determined the conformational epitopes in this longitudinal study by means of competition experiments using recombinant Fab of four GAD65-specific monoclonal antibodies. RESULTS: Sera from high-risk children in the preclinical stage recognise a specific combination of GAD65 antibody epitopes located in the middle and the C-terminus of GAD65. High risk of progressing to disease is associated with the emergence of antibodies specific for conformational epitopes at the N-terminus and the middle region. Binding to already established antibody epitopes located in the middle and at the N-terminus increases and shows a significant relation (p=0.005) with HLA, which confers risk of developing diabetes. CONCLUSIONS/ INTERPRETATION: In type 1 diabetes, GAD65 antibodies are initially generated against the middle and C-terminal regions of GAD65. In genetically predisposed subjects the autoimmune response may then undergo intramolecular epitope spreading towards epitopes on the N-terminus and further epitopes located in the middle. These findings clearly demonstrate that the GAD65 autoantibody response in the preclinical stage of type 1 diabetes is dynamic and related to the HLA genotypes that confer risk of diabetes. GAD65-specific Fab should prove useful in predicting progression from islet autoimmunity to clinical onset of type 1 diabetes.
Authors: W J Riley; N K Maclaren; J Krischer; R P Spillar; J H Silverstein; D A Schatz; S Schwartz; J Malone; S Shah; C Vadheim Journal: N Engl J Med Date: 1990-10-25 Impact factor: 91.245
Authors: C S Hampe; L P Hammerle; L Bekris; E Ortqvist; I Kockum; O Rolandsson; M Landin-Olsson; C Törn; B Persson; A Lernmark Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: J Graham; I Kockum; C B Sanjeevi; M Landin-Olsson; L Nyström; G Sundkvist; H Arnqvist; G Blohmé; F Lithner; B Littorin; B Scherstén; L Wibell; J Ostman; A Lernmark; N Breslow; G Dahlquist Journal: Eur J Immunogenet Date: 1999 Apr-Jun
Authors: S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren Journal: J Clin Invest Date: 1987-03 Impact factor: 14.808
Authors: A M Wägner; P Cloos; R Bergholdt; P Boissy; T L Andersen; D B Henriksen; C Christiansen; S Christgau; F Pociot; J Nerup Journal: Diabetologia Date: 2007-01-10 Impact factor: 10.122
Authors: Peter Arvan; Massimo Pietropaolo; David Ostrov; Christopher J Rhodes Journal: Cold Spring Harb Perspect Med Date: 2012-08-01 Impact factor: 6.915
Authors: T Maruyama; S Oak; T R Hall; J P Banga; E Ortqvist; R A Ettinger; J Endl; C S Hampe Journal: Clin Exp Immunol Date: 2007-10-22 Impact factor: 4.330
Authors: Tyler R Hall; Marika Bogdani; Renee C Leboeuf; Elizabeth A Kirk; Marlena Maziarz; J Paul Banga; Shilpa Oak; Christina A Pennington; Christiane S Hampe Journal: Immunology Date: 2007-11-14 Impact factor: 7.397
Authors: Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe Journal: Proc Natl Acad Sci U S A Date: 2008-03-26 Impact factor: 11.205